Powering Breast Cancer Progress Grant
Funding Amount
Up to US $250,000
Deadline
Deadline not published
Grant Type
Foundation
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Charitable and non-profit organizations involved in the care and support of patients with breast cancer
Other requirements
- Organizations must be registered as a charity or non-profit in their country.
Not eligible / not funded
- Not eligible: Eligible applicants include charitable organizations registered in their countries, while individuals and for-profits are excluded.
- Not eligible: Individuals, health care providers, medical group practices, public officials Organizations that: Discriminate on the basis of age, race, colour, religion, national origin, gender, sexual orientation, marital status, military service, veteran status, disability or other unlawful basis.
- Not eligible: Promote political or religious viewpoints to their beneficiaries Use the funds to make grants or donations to other organizations or individuals Are unable to supply bank details or report back on outcomes.
- Not eligible: Are non-charitable
- Not eligible: Initiatives already funded through other Astra.
- Not eligible: Zeneca programmes Projects that provide treatment or pay for medicines Projects that benefit AstraZeneca’s commercial business Applications over $250,000 (USD) Retrospective funding Capital projects or building appeals Any other activities prohibited under local standards
Overview
The Powering Breast Cancer Progress grant, funded by AstraZeneca and supported by CAF, aims to address inequities in breast cancer care globally. With a total funding of $500,000 for 2024, the program seeks innovative projects that can transform care for underserved populations. Two funding categories are available: $50,000-$100,000 and $100,001-$250,000, each offering technical advisory support. Eligible applicants include charitable organizations registered in their countries, while individuals and for-profits are excluded.
The Powering Breast Cancer Progress grant programme is an initiative funded by AstraZeneca and supported by the Charities Aid Foundation (CAF). It has been established in recognition of the inequities in breast cancer care around the world and the significant barriers to optimal care that are contributing to avoidable breast cancer deaths.
The programme aims to fund innovative and inspiring projects that could help transform breast cancer care for undeserved patient populations and patients living in areas of low socioeconomic status.
How Much Funding is Available?
In its first year, the Powering Breast Cancer Progress grant programme will support grantees with both a financial contribution and non-financial contribution.
Financial contribution:
The total fund size available for 2024 is $500,000 (USD). The funding will be provided by AstraZeneca through Charities Aid Foundation (CAF).
Non-financial contribution:
We understand the importance of supporting grantees to succeed with their projects. As such, non-financial support will also be offered alongside the financial contribution. Technical advisory support will be provided by Academy of Oncology Nurse and Patient Navigators (AONN), the largest national specialty organisation in the US dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. The allocation of hours of support will be determined by the size of the financial contribution.
There are two categories of funding. These are based upon the size of the applicant organization and the potential impact of the individual project
Category 1:
- Financial Contribution: $50,000 - $100,000 (USD)
- Non-financial Contribution: 3 hours of technical advisory support for AONN
- Category 2:
- Financial Contribution: $100,001 - $250,000
- Non-financial Contribution: 5 hours of technical advisory support for AONN
- Other Funding Considerations
The Powering Breast Cancer Progress grant request in most cases should not exceed 10% of the applicant organization’s annual revenue as stated in your annual accounts. However, we may fund some projects where funding is above this level. In exceptional circumstances, where an organization can demonstrate proven track record of delivering projects of similar scale/ scope, the threshold could be up to 50%. If you are requesting funding in excess of 10%, please provide evidence on your ability to manage this funding. Multiple applications are allowed from the same organization, but the combined sum of grants requested should not exceed 10% of the applicant organization’s annual revenue. Please provide a justification if the combined grant requests exceed 10% of the applicant organization’s annual revenue. Please request an appropriate level of funding according to your project needs, in line with one of the two categories available. Part of the assessment will focus on the transparency and breakdown of project costs, and partial funding may be awarded in some cases.
Eligibility
Powering Breast Cancer Progress grant applications are open to charitable and non-profit organizations involved in the care and support of patients with breast cancer. Organizations must be registered as a charity or non-profit in their country.
Ineligibility
Individuals, health care providers, medical group practices, public officials Organizations that: Discriminate on the basis of age, race, colour, religion, national origin, gender, sexual orientation, marital status, military service, veteran status, disability or other unlawful basisPromote political or religious viewpoints to their beneficiaries Use the funds to make grants or donations to other organizations or individuals Are unable to supply bank details or report back on outcomesAre non-charitable
Initiatives already funded through other AstraZeneca programmes Projects that provide treatment or pay for medicines Projects that benefit AstraZeneca’s commercial business Applications over $250,000 (USD) Retrospective funding Capital projects or building appeals Any other activities prohibited under local standards
What AstraZeneca Foundation actually gave
Source: IRS Form 990-PF, 2025
- Grants in 2025
- 7
- Total given
- $1.47M
- Median grant
- $250K
- Range
- $2,840–$250K
- By dollars: Pennsylvania 51%, District of Columbia 32%, Maryland 17%. Top recipient cities: Washington, DC; West Chester, PA; Baltimore, MD.
- 86% of grants with a stated purpose were for general or operating support.
Example grants
Community Volunteers in Medicine · West Chester, PA
Operational support - Creating Health Access for Next Generation Equity Program
$250K
Health Care for the Homeless Inc · Baltimore, MD
Operational support - Creating Health Access for Next Generation Equity Program
$250K
LCH Health and Community Services · Kennett Square, PA
Operational support - Creating Health Access for Next Generation Equity Program
$250K
Some Inc · Washington, DC
Operational support - Creating Health Access for Next Generation Equity Program
$250K
AIDS Resource Alliance Inc · Williamsport, PA
Operational support - Creating Health Access for Next Generation Equity Program
$250K
Focus Areas & Funding Uses
Fields of Work
- Cancer
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
January 7, 2027
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
National Institutes of Health
Amount
Varies
Deadline
October 25, 2027
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
National Institutes of Health
Amount
Varies
Deadline
October 25, 2027
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $350,000
Deadline
November 6, 2026
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$50,000 - $300,000
Deadline
November 10, 2026
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$50,000 - $150,000
Deadline
November 10, 2026
Ready to apply for Powering Breast Cancer Progress Grant?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Powering Breast Cancer Progress Grant. Now let's win it.